February 1, 2023
Adoptive cell therapy (ACT) with T-cells reprogrammed to express chimeric antigen receptors (CAR T-cells) bind specific antigens on the surface of cancer cells and trigger a cytotoxic response. CAR T-cell therapies have been successful in patients with hematological malignancies; however, patients remain at risk of relapse due to short-term persistence or non-expansion of CAR T-cells.1,2 This requirement for persistence is more evident in solid tumors as the hostile tumor microenvironment induces T-cell exhaustion.3,4 Studies have found that genomic and phenotypic features of CAR T-cells were major determinants of their persistence. Clinical results have shown that stemness and a memory-cell-like phenotype can promote sustained in vivo persistence of adoptively transferred CAR T-cells.3,4